NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
IYUZEH (latanoprost ophthalmic solution 0.005%) by Thea Pharma. Approved for prostaglandin analog [epc]. First approved in 2022.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IYUZEH is a latanoprost ophthalmic solution (0.005%) approved in December 2022 for glaucoma and ocular hypertension. It is a prostaglandin analog that reduces intraocular pressure by increasing uveoscleral outflow. The formulation represents Thea Pharma's entry into the competitive prostaglandin analog space for eye pressure management.
$0.252MPart D
Peak5.0 years to LOEEarly-stage peak product with modest current uptake (572 Part D claims in 2023); commercial team is focused on market penetration in the prostaglandin analog segment.
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IYUZEH offers career opportunities primarily in commercial, medical affairs, and market access roles focused on competing in a mature therapeutic category. Career growth depends on market share expansion and operational efficiency; limited pipeline extension or clinical advancement expected.
Brand ManagerMedical Science Liaison (MSL)
Worked on IYUZEH at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.